Related references
Note: Only part of the references are listed.Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia
Francesco Zaja et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
Waleed Ghanima et al.
BLOOD (2012)
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Vivek L. Patel et al.
BLOOD (2012)
Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis
Sophie Auger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Rituximab Maintenance Therapy for Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Claire Roubaud-Baudron et al.
JOURNAL OF RHEUMATOLOGY (2012)
B-cell depletion in the treatment of lupus nephritis
Jon W. Gregersen et al.
NATURE REVIEWS NEPHROLOGY (2012)
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Low-dose rituximab in adult patients with primary immune thrombocytopenia
Francesco Zaja et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab
Roberto Stasi et al.
BLOOD (2008)
Rituximab efficacy and. safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura:: results of a prospective multicenter phase 2 study
Bertrand Godeau et al.
BLOOD (2008)
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura
Francesco Zaja et al.
HAEMATOLOGICA (2008)
Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults
Drew Provan et al.
HAEMATOLOGICA (2007)
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
JCW Edwards et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
R Stasi et al.
BLOOD (2001)
Share Paper
